Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pfenex Awarded a Subcontract by Leidos

Published: Thursday, October 31, 2013
Last Updated: Thursday, October 31, 2013
Bookmark and Share
Funding will be provided by Leidos through its Malaria Vaccine Production and Support Services Contract with NIAID, part of the National Institutes of Health.

Pfenex Inc. has announced that Leidos Holdings, Inc. (formerly SAIC) has awarded Pfenex a subcontract to develop a robust, scalable, cGMP-ready production process for large-scale production of the blood-stage malaria antigen Plasmodium falciparum reticulocyte-binding homolog 5 (Rh5).

This contract is a result of successful pre-clinical studies performed by Leidos collaborators to evaluate the Rh5 antigen that was produced using the Pfēnex Expression Technology™ platform.

The subcontract is funded with federal funds from Leidos’ prime Malaria Vaccine Production and Support Services (MVPSS) contract (N01.AI.05421) from the National Institute of Allergy and Infectious Diseases (NIAID).

This is the second subcontract awarded to Pfenex for the development of critical, hard-to-express malaria antigens. Leidos had previously awarded Pfenex a subcontract to develop a scalable, cGMP-ready production process for large-scale production of full length Circumsporozoite protein (CSP) from P. falciparum.

“We are pleased to be awarded this contract as we expand our effort to find an effective therapy for malaria," stated Bertrand C. Liang, Pfenex’s Chief Executive Officer. “Pfēnex Expression Technology™ has once again demonstrated its ability to efficiently produce a high–value, complex protein enabling the potential of a multivalent malaria vaccine.”

Pfenex will immediately commence process development activities while continuing to provide materials to Leidos and NIAID for ongoing preclinical studies.

“Working with Pfenex and NIAID on this program is an important step in the development of an effective malaria vaccine,” said James Pannucci, Ph.D., vice president of the Leidos Health Life Sciences team. “We hope our work will lead to new discoveries and have a profound effect on the world’s health.”

The Leidos Life Science team operates a virtual drug development enterprise that bridges the gap between federal agencies and commercial clients, along with a modest portfolio of vaccine and therapeutic candidates.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pfenex and PATH Partner on Vaccines
Initiation of a multi-product research program with PATH.
Saturday, October 11, 2014
Pfenex Awards a Contract to Paragon Bioservices
Contract for cGMP manufacturing of recombinant protective antigen, for phase 1 clinical trial of Company’s anthrax vaccine.
Thursday, November 07, 2013
Scientific News
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!